PubMed Health⌕ Search

PubMed · 11970337

Heavy-ion-beam-induced hydrodynamic effects in solid targets.

Abstract

It is expected that after the completion of a new high current injector, the heavy-ion synchrotron (SIS) at the Gesellschaft für Schwerionforschung (GSI) Darmstadt will accelerate U(+28) ions to energies of the order of 200 MeV/u. The use of a powerful rf buncher will reduce the pulse length to about 50 ns, and employment of a multiturn injection scheme will provide 2 x 10(11) particles in the beam that correspond to a total energy of the order of 1 kJ. This upgrade of the SIS, hopefully, will be completed by the end of the year 2001. These beam parameters lead to a specific power deposition of the order of 1-2 TW/g in solid matter that will provide temperatures of about 10 eV. Such low specific power deposition will induce hydrodynamic effects in solid materials, and one may design appropriate beam-target interaction experiments that could be used to investigate the equation of state of matter under extreme conditions. The purpose of this paper is to propose suitable target designs with optimized parameters for the future GSI experiments with the help of one and two-dimensional hydrodynamic simulations. Cylindrical geometry is the natural geometry for highly focused ion beams, and therefore cylindrical targets are the most appropriate for this type of interaction experiments. The numerical simulations presented in this paper show that one can experimentally measure the characteristic sound speed in beam heated targets which is an important physical parameter. Moreover, one can study the propagation of ion-beam-induced shock waves in the solid materials. Different values for the specific power deposition, namely, 10, 25, 50, and 100 kJ/g, have been used. In some cases the pulse length is assumed to be 40 ns while in others it is considered to be 50 ns. Various materials including lead, aluminum, and solid neon have been used.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

N A Tahir, D H Hoffmann, J A Maruhn, P Spiller, R Bock. 1999. Heavy-ion-beam-induced hydrodynamic effects in solid targets.. https://doi.org/10.1103/physreve.60.4715

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗